Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-09-23 am EDT
1313.20 GBX   +1.33%
09/24JULIE BROWN : GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News
RE
09/24GSK Poaches Burberry CFO To Create All-Female Top Team - Sky News
RE
09/24Julie brown, will be unveiled next week as the new chief financi…
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK takes stake in Spero in deal for experimental UTI treatment

09/22/2022 | 02:30am EDT
Illustration shows GSK (GlaxoSmithKline) logo

(Reuters) - British drugmaker GSK said on Thursday it would take a stake in Spero Therapeutics as part of a licensing agreement for the U.S.-based drug developer's experimental antibiotic for complicated urinary tract infections.

GSK will pay Spero $66 million upfront for the antibiotic tebipenem HBr and buy $9 million of Spero shares, the companies said in a joint statement.

(Reporting by Amna Karimi in Bengaluru; Editing by Sriraj Kalluvila)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 1.33% 1313.2 Delayed Quote.-20.10%
SPERO THERAPEUTICS, INC. -10.45% 1.97 Delayed Quote.-87.70%
All news about GSK PLC
09/24JULIE BROWN : GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky New..
RE
09/24GSK Poaches Burberry CFO To Create All-Female Top Team - Sky News
RE
09/24Julie brown, will be unveiled next week as the new chief financi…
RE
09/24Gsk poaches burberry cfo to create all-female top team - sky new…
RE
09/23GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a la..
AQ
09/23Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA..
AQ
09/23GSK Says US Food and Drug Administration to Convene ODAC Meeting to Review Data of Zeju..
MT
09/23LONDON STOCK EXCHANGE : FTSE muted ahead of UK's mini-budget
RE
09/22ADRs End Mostly Lower; Compagnie de Saint-Gobain Trades Actively
DJ
09/22SECTOR UPDATE : Health Care Stocks Gain Thursday Afternoon
MT
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 28 226 M 30 859 M 30 859 M
Net income 2022 4 503 M 4 923 M 4 923 M
Net Debt 2022 14 354 M 15 693 M 15 693 M
P/E ratio 2022 11,3x
Yield 2022 4,67%
Capitalization 53 163 M 58 121 M 58 121 M
EV / Sales 2022 2,39x
EV / Sales 2023 2,25x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 313,20 GBX
Average target price 1 874,20 GBX
Spread / Average Target 42,7%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-20.10%58 121
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392